Among patients with PSA levels 0 to 1.99 ng/mL, use of upfront PSMA-PET vs conventional imaging was estimated to result in an increase of 921 life-years (95% UI, 845-1013 life-years) and 784 QALYs (95% UI, 727-883 QALYs) and 71 fewer deaths (95% UI, 66-74 deaths) from prostate cancer. This evidence concerns the gene FOLH1 and prostate carcinoma.